Li Lab: Difference between revisions

From OpenWetWare
Jump to navigationJump to search
(220 intermediate revisions by 2 users not shown)
Line 6: Line 6:
<div style="float:left;margin-left:0.3em;margin-right:0.7em">
<div style="float:left;margin-left:0.3em;margin-right:0.7em">


== '''Welcome to Wei Li's Computational Genomics Lab''' ==  
== '''Computational Cancer Epigenomics and Transcriptomics (PI: Wei Li)''' ==  


[http://www.bcm.edu/cancercenter/ Dan L. Duncan Cancer Center], [http://www.bcm.edu/mcb/index.html Department of Molecular and Cellular Biology], [http://www.bcm.edu/ Baylor College of Medicine]
[http://www.bcm.edu/cancercenter/ Dan L. Duncan Cancer Center], [http://www.bcm.edu/mcb/index.html Department of Molecular and Cellular Biology], [http://www.bcm.edu/ Baylor College of Medicine]
Line 15: Line 15:


==Recent News==
==Recent News==
. 12/2010: Liguo's fly RNA-seq paper has been published in  '''Genome Research'''.
. 06/16: A new paper w/ MG Lee @ MD Anderson was accepted to '''Molecular Cell'''.


. 10/2010: A Texas '''CPRIT grant''' has been funded. We will work with Dr. Goodell at BCM to understand DNA Methylgransferase 3B in normal and malignant hematopoiesis.  
. 05/16: Zheng Xia has been offered (in principle) a '''tenure-track faculty position'''. Congratulations!


. 08/2010: Our '''Pilot Project''' has been funded by a NIH Stem Cell P01 Grant.  
. 04/16: Jianzhong's DNMT3A/TET2 paper (w/ Goodell lab) was accepted to '''Nature Genetics'''.  


. 07/2010: The DNA methylation platform comparision paper has been accepted to '''Nature Biotechnology'''.
. 04/16: Wei has been selected as a recipient of the 2016 [https://www.bcm.edu/news/awards-honors-faculty-staff/2016-debakey-research-award-science  '''Michael E. DeBakey, M.D., Excellence in Research Award''']


. 06/2010: Hao Zhao will join us as a '''postdoc fellow'''. Hao has a PhD in Computer Science from City University of Hong Kong. Welcome!  
. 04/16: Yuanxin has been offered a '''tenure-track faculty position''' at The University of Texas Health Science Center at Houston (UTHealth). Congratulations!


. 05/2010Our paper titled "Histone modifications and chromatin organization in prostate cancer" has been accepted by '''Epigenomics'''.
. 03/2016Ben's enhancer hypomethylation paper (w/ Goodell lab) was accepted to '''Cancer Cell'''.  


. 01/2010A Texas '''CPRIT grant''' has been funded. We will use ChIP-seq and RNA-seq to analyze Androgen Receptor (AR) function in Prostate Cancer with Dr. Weigel at BCM.
. 02/2016Yuanxin's SIRT6 paper (w/ Chua lab at Stanford) was accepted to '''Nature Structural & Molecular Biology'''


. 01/2010: A '''CPRIT multi-investigator planning award''' has been funded. This project will bring together a "dream team" in epigenetics research.  We will direct the bioinformatics component for LONESTAR.
. 01/2016: Welcome our new Postdoc Associate Dr. Jie Lyu.


. 01/2010Wei Li is an invited speaker in the American Association for Cancer Research (AACR) Special '''Conference on Cancer Epigenetics''' at Puerto Rico.
. 12/2015Yuanxin's G9a paper (w/ Shi lab at MD Anderson) was accepted to '''Nature Communications. '''


. 12/24/2009Dr.Bert O'Malley's SRC-3 ChIP-seq paper has been accepted by '''Molecular Endocrinology'''. Liguo and Wei are co-authors on the paper.
. 12/2015Kaifu's UTX paper (w/ Lee lab at MD Anderson) was accepted to '''Nucleic Acids Research '''.  


. 12/08/2009: Liguo's RNA-seq methodology paper has been accepted by '''PLoS ONE'''. Congratulations Liguo!
. 11/2015: We received a new '''NIH/NCI R01''' grant (scored at 5%ile) to study 3`UTR alternations in human cancers.


. 11/13/2009: Wei Li received a '''New Investigator Award''' from the Department of Defense (DOD) Prostate Cancer Research Program (PCRP). Cheers!
. 09/2015: Welcome our new Research Associate (and potential Graduate Student) YanBing Cheng.


. 11/07/2009: Wei Li gave a '''Keynote Presentation''' at the Symposium on Advances in Cell Signaling, Cancer Prevention and Therapy at South Padre Island, Texas.
. 08/2015: Kaifu's Cancer Big-data analysis paper is published in '''Nature Genetics'''. This work links broad H3K4me3 to pan-cancer tumor suppressors. See reports in Nature Editor’s [http://blogs.nature.com/freeassociation/2015/08/methylation-marks-tumor-suppressors.html Blog], [http://cancerdiscovery.aacrjournals.org/content/early/2015/09/01/2159-8290.CD-RW2015-166.abstract Cancer Discovery], [http://www.ebiotrade.com/newsf/2015-8/2015825165005119.htm ebiotrade.com] (in Chinese), [http://fromthelabs.bcm.edu/2015/10/15/novel-epigenetic-signature-for-tumor-suppressors-in-normal-cells-found/ BCM news] and [http://cancer.osu.edu/news-and-media/news/studies-suggest-new-ways-to-inhibit-oncogenes-enhance-tumor-suppressor-activity OSU news]; and an error we found in a [http://www.cell.com/cell/fulltext/S0092-8674(15)01407-5 Cell paper].


. 09/29/2009A prestigious '''NIH Challenge grant''' has been funded. We will use ChIP-seq to analyze RXRa binding in mouse liver with Dr. Karpen at Texas Children's Hospital.
. 07/2015Wei will become a regular member of the '''NIH GCAT''' (Genomics, Computational Biology and Technology) study section.


. 09/17/2009: A two-year $2.5 million '''NIH Grand Opportunity (GO) grant''' has been funded. We will study aging epigenomics with Drs. Darlington and Goodell at BCM.
. 06/2015: Kaifu will start his '''tenure-track faculty''' position at Cornell University & Methodist Hospital. Congratulations!


. 09/15/2009A prestigious '''NIH Challenge grant''' has been funded. We will use RNA-seq to characterize patient cardiac progenitors with Dr. Pu at Harvard Medical School.
. 03/2015Kaifu's MeCP2 mCH binding paper (w/ Zoghbi lab) is accepted to '''PNAS'''.


. 06/05/2009: Yuanxin's Bisulfite Sequence Mapping paper has been accepted by '''BMC Bioinformatics'''. Congratulations Yuanxin!
. 3/2015: We received a NEW '''CPRIT''' grant.


. 03/26/2009Wei's paper titled 'Reprogrammed Androgen Receptor Function in Androgen-Independent Prostate Cancer' has been accepted by '''Cell'''.
. 01/2015Deqiang, HJ and Ben's HSC novel noncoding RNA paper is accepted to '''Cell Stem Cell''' -- the 100th paper we published.


. 12/2014:  Zheng Xia is awarded a '''Keck fellowship''' in Computational Cancer Biology.


. 11/2014:  Zheng's DaPars 3'UTR Pan Cancer analysis paper is published in '''Nature Communications'''.
. 09/2014:  Liguo's ChIP-exo methodology paper (MACE) is accepted to '''Nucleic Acids Research'''.  MACE is recommended by Active Motif as the software solution for the company's new [https://www.activemotif.com/catalog/1050/chip-exo ChIP-exo kit and service].
. 09/2014: Deqiang will start his '''tenure-track assistant professor''' position. Job well done. 
. 09/2014:  Zheng's prostate cancer RNA-seq paper with Dr. Balk at Harvard is accepted to '''Molecular Cancer Research '''.
. 09/2014:  Yuanxin's work on H3K79 Methylation with Dr. Shi is accepted to '''Cell'''.
. 08/2014:  '''Three Collaborative CPRIT grants''' are funded: DNA methylation with Goodell lab, 3'UTR with Wagner lab and ZM11 with Shi lab.
. 06/2014:  Deqiang's Dnmt3a/3b double KO paper (w/ Goodell Lab) is accepted to '''Cell Stem Cell '''.
. 06/2014:  Zheng's alternative splicing paper (w/ Cooper Lab) is accepted to '''Molecular Cell '''.
. 02/2014:  Zheng's brain tumor 3'UTR regulator paper is accepted to '''Nature'''. This paper was initially rejected after review twice. We appealed twice with success and finally made it in the 3rd submission.
. 02/2014:  Welcome our new postdoc Jianzhong Su and graduate student Xueqiu Lin.
. 02/2014:  Deqiang's mouse HSC Aging Epigenomics paper is accepted in principle to '''Cell Stem Cell'''.
. 01/2014:  Deqiang's Methodology paper for the detection of differential DNA Methylation (MOABS) is accepted to '''Genome Biology'''.
. 01/2014:  Yuanxin and Zheng's ZM11 paper with Xiaobing Shi lab in MD Anderson is accepted to '''Nature'''. This work links transcription elongation to tumor suppression.
[[Image:Banner.jpg‎‎]]


[http://openwetware.org/wiki/Li_Lab:news News Archive]
[http://openwetware.org/wiki/Li_Lab:news News Archive]
Line 57: Line 87:
{|width="*"
{|width="*"
|
|
{| style="width: 100%;  text-align:center;font-size:12px;font-variant: small-caps;width: 18px; " align="center"  
{| style="width: 728px;  text-align:center;font-size:12px;font-variant: small-caps;width: 18px; " align="center"  
|-
|-


Line 73: Line 103:
<div style="border-bottom: 1px dashed #9999CC;">
<div style="border-bottom: 1px dashed #9999CC;">


== '''A Genomic View of Epigenetic and Transcriptional Regulation''' ==
Our lab is focused on the design and application of bioinformatics algorithms to elucidate global epigenetic mechanisms and transcription dynamics in normal development and diseases such as cancer. Since establishing the lab in early 2008, we have
* '''Published''' >86 peer-reviewed papers through solid methodology development and extensive collaboration research, including >34 in '''Nature, Science and Cell''' series.
 
* '''Been well-funded''' by NIH and Texas CPRIT with total external funding >$1.3 million per year. Dr Li is the PI on the following 4 major grants: NIH R01HG007538 (2013-2018) and R01CA193466 (2015-2020); CPRIT RP110471-C3 (2011-2016) and RP150292 (2015-2018).
* '''Mentored''' the first 3 postdoc trainees to start their tenure track faculty positions in prestigious research institutions in the US.
 
We have developed a number of widely used algorithms to analyze next generation sequencing data from ChIP-seq (MACS, MACE), DNA methylation Bisulfite-seq (BSMAP/RRBSMAP, BSeQC, MOABS), nucleosome positioning MNase-seq (DANPOS), and RNA-seq (CPAT, RSeQC, DaPars). These algorithms have been broadly adopted by thousands of academic users. For example, the MACS algorithm has gathered >1900 citations since 2008.


In collaboration with experimental biologists, we used these algorithms to gain novel biological insights from various biological processes and disease models.


Our lab is focused on the design and application of bioinformatics algorithms to elucidate global regulatory mechanism by integrating data from ChIP-seq, DNA methylation, Nucleosome positioning, and RNA-seq. We are also working with bench and clinical collaborators to understand epigenetic gene regulation in various biological processes and disease models.  
* '''Chromatin Factors''': ER in breast cancer, AR in prostate cancer, FoxA1 pioneer factor, Atoh1 in neuron development, NSD2 in oncogenic programming, SIRT7 in cancer transformation, ZM11 in transcription elongation, and p53 in ES differentiation..


An elaborate system of epigenetic and transcription regulation is responsible for the morphological and behavioral complexity in higher eukaryotes. This regulatory system consists of diverse trans-acting protein factors, cis-acting regulatory DNA sequences and the underlying epigenomic background, such as histone modifications, DNA methylation and Nucleosome localizations. Recently, Chromatin ImmunoPrecipitation coupled with whole genome tiled microarray (ChIP-chip) and/or next-generation sequencing (Solexa, SOLiD and 454) has evolved as a powerful and unbiased technique to study this genome-wide regulatory system. The application of this technology to multiple factors and/or in multiple conditions allows biologists to study how transcription is differentially regulated in a combinatorial manner. However, it also poses great challenges for the development of effective algorithms, the key link between massive raw data and biological hypotheses.
* '''DNA Methylation''': DNA methylation Canyon, Epigenetic changes in HSC aging, Dnmt3a in HSC differentiation and cancer transformation.  


We have developed a number of widely used algorithms to detect and annotate genome-wide cis-regulatory regions, including a Hidden Markov Model (Bioinformatics 2005) and MAT (PNAS 2006) for analyzing ChIP-chip experiments on genome tiling arrays, CEAS (NAR 2006) for cis-regulatory element annotation, xMAN (BMC Genomics 2008) for microarray probe mapping, MACS (Genome Biology 2008) for model based analysis of ChIP-seq, BSMAP (BMC Bioinformatics 2009) for DNA methylation analysis using Bisulfite-seq, and MMES (PLoS ONE 2010) for alternative splicing using RNA-seq. These algorithms have gathered thousands of academic users worldwide and hundreds of citations, including > 30 papers in Cell and Nature serious. We are currently actively working on bioinformatics development for 1) Transcription factor binding and histone modifications (ChIP-seq); 2) DNA methylation at single nucleotide resolution (Bisulfite-seq); 3) Nucleosome remodeling (Mnase-seq); 4) Alternative splicing (RNA-seq).
* '''Nucleosome Organization''': Fragile nucleosome in stress-response, Promoter nucleosome with Tup1, Nucleosome dynamics in ES differentiation, and Global nucleosome loss in yeast aging.


We also have extensive experience in collaborative research, such as Estrogen Receptor (ER) in breast cancer (Cell 2005; Nature Genetics 2006), Androgen Receptor (AR) in prostate cancer (Molecular Cell 2007; Cell 2009) and ER/AR’s collaborating factor FoxA1 (Cell 2008). My laboratory also plays an important role in the BCM Epigenomics Data Analysis and Coordination Center for a five-year [http://nihroadmap.nih.gov/epigenomics/referenceepigenomeconsortium.asp NIH Roadmap Epigenomics Program].  
* '''Transcriptome''': chimeric RNA in prostate cancer, Long non-coding RNA in HSC, 3’UTR deletion in cancer and its master regulator CFIm25. .


[http://sites.google.com/a/bcm.edu/lilab/ Lab Intranet]
[http://sites.google.com/a/bcm.edu/lilab/ Lab Intranet]
[http://openwetware.org/wiki/Li_Lab openwetware]
[http://openwetware.org/wiki/Li_Lab openwetware]

Revision as of 14:56, 1 June 2016

Home        People        Publications        Collaborations        Software        Positions        Contact       


Recent News

. 06/16: A new paper w/ MG Lee @ MD Anderson was accepted to Molecular Cell.

. 05/16: Zheng Xia has been offered (in principle) a tenure-track faculty position. Congratulations!

. 04/16: Jianzhong's DNMT3A/TET2 paper (w/ Goodell lab) was accepted to Nature Genetics.

. 04/16: Wei has been selected as a recipient of the 2016 Michael E. DeBakey, M.D., Excellence in Research Award

. 04/16: Yuanxin has been offered a tenure-track faculty position at The University of Texas Health Science Center at Houston (UTHealth). Congratulations!

. 03/2016: Ben's enhancer hypomethylation paper (w/ Goodell lab) was accepted to Cancer Cell.

. 02/2016: Yuanxin's SIRT6 paper (w/ Chua lab at Stanford) was accepted to Nature Structural & Molecular Biology

. 01/2016: Welcome our new Postdoc Associate Dr. Jie Lyu.

. 12/2015: Yuanxin's G9a paper (w/ Shi lab at MD Anderson) was accepted to Nature Communications.

. 12/2015: Kaifu's UTX paper (w/ Lee lab at MD Anderson) was accepted to Nucleic Acids Research .

. 11/2015: We received a new NIH/NCI R01 grant (scored at 5%ile) to study 3`UTR alternations in human cancers.

. 09/2015: Welcome our new Research Associate (and potential Graduate Student) YanBing Cheng.

. 08/2015: Kaifu's Cancer Big-data analysis paper is published in Nature Genetics. This work links broad H3K4me3 to pan-cancer tumor suppressors. See reports in Nature Editor’s Blog, Cancer Discovery, ebiotrade.com (in Chinese), BCM news and OSU news; and an error we found in a Cell paper.

. 07/2015: Wei will become a regular member of the NIH GCAT (Genomics, Computational Biology and Technology) study section.

. 06/2015: Kaifu will start his tenure-track faculty position at Cornell University & Methodist Hospital. Congratulations!

. 03/2015: Kaifu's MeCP2 mCH binding paper (w/ Zoghbi lab) is accepted to PNAS.

. 3/2015: We received a NEW CPRIT grant.

. 01/2015: Deqiang, HJ and Ben's HSC novel noncoding RNA paper is accepted to Cell Stem Cell -- the 100th paper we published.

. 12/2014: Zheng Xia is awarded a Keck fellowship in Computational Cancer Biology.

. 11/2014: Zheng's DaPars 3'UTR Pan Cancer analysis paper is published in Nature Communications.

. 09/2014: Liguo's ChIP-exo methodology paper (MACE) is accepted to Nucleic Acids Research. MACE is recommended by Active Motif as the software solution for the company's new ChIP-exo kit and service.

. 09/2014: Deqiang will start his tenure-track assistant professor position. Job well done.

. 09/2014: Zheng's prostate cancer RNA-seq paper with Dr. Balk at Harvard is accepted to Molecular Cancer Research .

. 09/2014: Yuanxin's work on H3K79 Methylation with Dr. Shi is accepted to Cell.

. 08/2014: Three Collaborative CPRIT grants are funded: DNA methylation with Goodell lab, 3'UTR with Wagner lab and ZM11 with Shi lab.

. 06/2014: Deqiang's Dnmt3a/3b double KO paper (w/ Goodell Lab) is accepted to Cell Stem Cell .

. 06/2014: Zheng's alternative splicing paper (w/ Cooper Lab) is accepted to Molecular Cell .

. 02/2014: Zheng's brain tumor 3'UTR regulator paper is accepted to Nature. This paper was initially rejected after review twice. We appealed twice with success and finally made it in the 3rd submission.

. 02/2014: Welcome our new postdoc Jianzhong Su and graduate student Xueqiu Lin.

. 02/2014: Deqiang's mouse HSC Aging Epigenomics paper is accepted in principle to Cell Stem Cell.

. 01/2014: Deqiang's Methodology paper for the detection of differential DNA Methylation (MOABS) is accepted to Genome Biology.

. 01/2014: Yuanxin and Zheng's ZM11 paper with Xiaobing Shi lab in MD Anderson is accepted to Nature. This work links transcription elongation to tumor suppression.


News Archive




Our lab is focused on the design and application of bioinformatics algorithms to elucidate global epigenetic mechanisms and transcription dynamics in normal development and diseases such as cancer. Since establishing the lab in early 2008, we have

  • Published >86 peer-reviewed papers through solid methodology development and extensive collaboration research, including >34 in Nature, Science and Cell series.
  • Been well-funded by NIH and Texas CPRIT with total external funding >$1.3 million per year. Dr Li is the PI on the following 4 major grants: NIH R01HG007538 (2013-2018) and R01CA193466 (2015-2020); CPRIT RP110471-C3 (2011-2016) and RP150292 (2015-2018).
  • Mentored the first 3 postdoc trainees to start their tenure track faculty positions in prestigious research institutions in the US.

We have developed a number of widely used algorithms to analyze next generation sequencing data from ChIP-seq (MACS, MACE), DNA methylation Bisulfite-seq (BSMAP/RRBSMAP, BSeQC, MOABS), nucleosome positioning MNase-seq (DANPOS), and RNA-seq (CPAT, RSeQC, DaPars). These algorithms have been broadly adopted by thousands of academic users. For example, the MACS algorithm has gathered >1900 citations since 2008.

In collaboration with experimental biologists, we used these algorithms to gain novel biological insights from various biological processes and disease models.

  • Chromatin Factors: ER in breast cancer, AR in prostate cancer, FoxA1 pioneer factor, Atoh1 in neuron development, NSD2 in oncogenic programming, SIRT7 in cancer transformation, ZM11 in transcription elongation, and p53 in ES differentiation..
  • DNA Methylation: DNA methylation Canyon, Epigenetic changes in HSC aging, Dnmt3a in HSC differentiation and cancer transformation.
  • Nucleosome Organization: Fragile nucleosome in stress-response, Promoter nucleosome with Tup1, Nucleosome dynamics in ES differentiation, and Global nucleosome loss in yeast aging.
  • Transcriptome: chimeric RNA in prostate cancer, Long non-coding RNA in HSC, 3’UTR deletion in cancer and its master regulator CFIm25. .


Lab Intranet openwetware


<html> <script type="text/javascript">

 var _gaq = _gaq || [];
 _gaq.push(['_setAccount', 'UA-5924762-2']);
 _gaq.push(['_trackPageview']);
 (function() {
   var ga = document.createElement('script'); ga.type = 'text/javascript'; ga.async = true;
   ga.src = ('https:' == document.location.protocol ? 'https://ssl' : 'http://www') + '.google-analytics.com/ga.js';
   var s = document.getElementsByTagName('script')[0]; s.parentNode.insertBefore(ga, s);
 })();

</script> </html>